Logo image of CMPX

COMPASS THERAPEUTICS INC (CMPX) Stock Fundamental Analysis

NASDAQ:CMPX - Nasdaq - US20454B1044 - Common Stock - Currency: USD

1.89  +0.07 (+3.85%)

After market: 1.88 -0.01 (-0.53%)

Fundamental Rating

3

Overall CMPX gets a fundamental rating of 3 out of 10. We evaluated CMPX against 563 industry peers in the Biotechnology industry. CMPX has a great financial health rating, but its profitability evaluates not so good. CMPX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CMPX had negative earnings in the past year.
CMPX had a negative operating cash flow in the past year.
In the past 5 years CMPX always reported negative net income.
In the past 5 years CMPX always reported negative operating cash flow.
CMPX Yearly Net Income VS EBIT VS OCF VS FCFCMPX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

With a decent Return On Assets value of -35.17%, CMPX is doing good in the industry, outperforming 60.85% of the companies in the same industry.
CMPX has a better Return On Equity (-39.43%) than 71.25% of its industry peers.
Industry RankSector Rank
ROA -35.17%
ROE -39.43%
ROIC N/A
ROA(3y)-27.3%
ROA(5y)-38.44%
ROE(3y)-29.88%
ROE(5y)-44.45%
ROIC(3y)N/A
ROIC(5y)N/A
CMPX Yearly ROA, ROE, ROICCMPX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CMPX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CMPX Yearly Profit, Operating, Gross MarginsCMPX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K

More info and screens

8

2. Health

2.1 Basic Checks

CMPX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CMPX has been increased compared to 1 year ago.
Compared to 5 years ago, CMPX has more shares outstanding
There is no outstanding debt for CMPX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CMPX Yearly Shares OutstandingCMPX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
CMPX Yearly Total Debt VS Total AssetsCMPX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

CMPX has an Altman-Z score of 6.43. This indicates that CMPX is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 6.43, CMPX belongs to the top of the industry, outperforming 82.36% of the companies in the same industry.
CMPX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.43
ROIC/WACCN/A
WACC10.09%
CMPX Yearly LT Debt VS Equity VS FCFCMPX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 14.96 indicates that CMPX has no problem at all paying its short term obligations.
The Current ratio of CMPX (14.96) is better than 90.12% of its industry peers.
CMPX has a Quick Ratio of 14.96. This indicates that CMPX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of CMPX (14.96) is better than 90.30% of its industry peers.
Industry RankSector Rank
Current Ratio 14.96
Quick Ratio 14.96
CMPX Yearly Current Assets VS Current LiabilitesCMPX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

3

3. Growth

3.1 Past

CMPX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -8.82%.
EPS 1Y (TTM)-8.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CMPX will show a very strong growth in Earnings Per Share. The EPS will grow by 34.17% on average per year.
The Revenue is expected to grow by 237.86% on average over the next years. This is a very strong growth
EPS Next Y-28.02%
EPS Next 2Y-20.07%
EPS Next 3Y10.11%
EPS Next 5Y34.17%
Revenue Next Year40.17%
Revenue Next 2Y517.78%
Revenue Next 3Y431.13%
Revenue Next 5Y237.86%

3.3 Evolution

CMPX Yearly Revenue VS EstimatesCMPX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B 2.5B
CMPX Yearly EPS VS EstimatesCMPX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 4 6 8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CMPX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CMPX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CMPX Price Earnings VS Forward Price EarningsCMPX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CMPX Per share dataCMPX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6 0.8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-20.07%
EPS Next 3Y10.11%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CMPX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COMPASS THERAPEUTICS INC

NASDAQ:CMPX (5/2/2025, 8:00:00 PM)

After market: 1.88 -0.01 (-0.53%)

1.89

+0.07 (+3.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-27 2025-02-27/bmo
Earnings (Next)05-12 2025-05-12/bmo
Inst Owners53.95%
Inst Owner Change0.7%
Ins Owners6.82%
Ins Owner Change2.81%
Market Cap261.35M
Analysts88.75
Price Target11.93 (531.22%)
Short Float %8.46%
Short Ratio5.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)10.43%
Min EPS beat(2)-9.93%
Max EPS beat(2)30.79%
EPS beat(4)2
Avg EPS beat(4)12.04%
Min EPS beat(4)-9.93%
Max EPS beat(4)30.79%
EPS beat(8)4
Avg EPS beat(8)12.23%
EPS beat(12)7
Avg EPS beat(12)12.08%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.63%
PT rev (3m)6.36%
EPS NQ rev (1m)-1.83%
EPS NQ rev (3m)-48%
EPS NY rev (1m)-2.74%
EPS NY rev (3m)-16.79%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-80.21%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 307.47
P/FCF N/A
P/OCF N/A
P/B 2.09
P/tB 2.09
EV/EBITDA N/A
EPS(TTM)-0.37
EYN/A
EPS(NY)-0.47
Fwd EYN/A
FCF(TTM)-0.32
FCFYN/A
OCF(TTM)-0.32
OCFYN/A
SpS0.01
BVpS0.91
TBVpS0.91
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -35.17%
ROE -39.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.3%
ROA(5y)-38.44%
ROE(3y)-29.88%
ROE(5y)-44.45%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.47%
Cap/Sales 5.18%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.96
Quick Ratio 14.96
Altman-Z 6.43
F-Score4
WACC10.09%
ROIC/WACCN/A
Cap/Depr(3y)12.9%
Cap/Depr(5y)74.97%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-28.02%
EPS Next 2Y-20.07%
EPS Next 3Y10.11%
EPS Next 5Y34.17%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year40.17%
Revenue Next 2Y517.78%
Revenue Next 3Y431.13%
Revenue Next 5Y237.86%
EBIT growth 1Y-12.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-27.18%
EBIT Next 3Y18.27%
EBIT Next 5Y35.27%
FCF growth 1Y-10.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-10.43%
OCF growth 3YN/A
OCF growth 5YN/A